The Latest Breaking News from GSK

Moderna stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months.

Price of asthma inhalers has more than doubled amid scarcity and added costs after GSK exited Nigerian market in 2023.

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results.

The H5N1 virus has been devastating bird populations, and is now infecting mammals too. Is human-to-human transmission next? And are we ready for another pandemic?

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

This covered call equates to a 6.26% return, or 22.17% on an annualized basis.